title: The Mayo Clinic experience with multimodality treatment of locally advanced or recurrent colon cancer.
abstract: BACKGROUND
  Patients with incompletely resected locally advanced and recurrent colon cancers have a dismal prognosis. Since 1981, 100 colon cancer patients have been treated with combination therapy including surgical resection, chemotherapy, and external plus intraoperative radiotherapy.
  
  
  METHODS
  A prospective computerized intraoperative radiation database identified patients for this retrospective review. Data collection included patient demographics, tumor and treatment variables, and morbidity, recurrence, and survival statistics.
  
  
  RESULTS
  The mean age was 55.2 years. Follow-up was available for all patients. Fifty-nine patients have died. Median follow-up of survivors was 70.5 months. Twenty-five patients with locally advanced colon cancer had a median survival of 38.2 months and a 5-year survival of 49%. Eleven of these patients are still free of disease. Seventy-three patients treated for recurrent colon carcinoma had a median survival of 33.3 months from the time of recurrence, with a 5-year survival of 24.7%. Twenty-one are alive without evidence of recurrence. The 38 patients with recurrent disease whose disease was completely resected had a 37.4% 5-year survival.
  
  
  CONCLUSIONS
  A multimodality approach using en-bloc surgical resection with radiotherapy and chemotherapy affords some patients with locally advanced and recurrent colon cancer a chance for long-term survival.
authors.affiliation: Department of Surgery, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
authors.forename: William E
authors.initials: WE
authors.lastname: Taylor
authors.forename: John H
authors.initials: JH
authors.lastname: Donohue
authors.forename: Leonard L
authors.initials: LL
authors.lastname: Gunderson
authors.forename: Heidi
authors.initials: H
authors.lastname: Nelson
authors.forename: David M
authors.initials: DM
authors.lastname: Nagorney
authors.forename: Richard M
authors.initials: RM
authors.lastname: Devine
authors.forename: Michael G
authors.initials: MG
authors.lastname: Haddock
authors.forename: Dirk R
authors.initials: DR
authors.lastname: Larson
authors.forename: Joseph
authors.initials: J
authors.lastname: Rubin
authors.forename: Michael J
authors.initials: MJ
authors.lastname: O'Connell
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D003082:Colectomy; D003110:Colonic Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary / Q000628:therapy; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D007430:Intraoperative Care; D008297:Male; D008875:Middle Aged; D008910:Minnesota / Q000453:epidemiology; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods*; D015996:Survival Rate
chemical_list: D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil